Y-mAbs Therapeutics (YMAB) has been the subject of analysis by four analysts over the past three months, with a mix of bullish and bearish perspectives. In the table provided, we can see a summary of their recent ratings, which show a shifting sentiment over the past 30 days compared to previous months.
The analysts have provided a range of ratings, from bullish to bearish, with three analysts being bullish, one somewhat bullish, and none bearish in the past 30 days. This indicates a positive outlook on the company’s future prospects. Looking back over the past month, there have been two bullish ratings and one somewhat bullish rating, showing a consistent positive sentiment towards YMAB.
In terms of price targets, the analysts have provided an average target of $23.75, with a high estimate of $26.00 and a low estimate of $21.00. This represents an increase of 35.71% from the previous average price target of $17.50. This indicates that analysts are optimistic about the potential growth of YMAB in the coming months.
Analysts play a crucial role in providing insights into the performance and potential of a company like Y-mAbs Therapeutics. By analyzing their ratings, actions, and price targets, investors can gain valuable information on the market sentiment towards the stock. Understanding these evaluations alongside key financial indicators can offer valuable insights into YMAB’s market standing and help investors make well-informed decisions.
Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer. The company’s first FDA-approved product, DANYELZA, targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
In terms of financial performance, Y-mAbs Therapeutics has a strong market capitalization, indicating a strong market presence. However, the company has experienced a decline in revenue growth over the past three months, which lags behind its industry peers. Despite this, the company has shown strong profitability with a high net margin and return on equity and assets.
Overall, analysts are bullish on the future prospects of Y-mAbs Therapeutics, with positive ratings and price targets indicating optimism for the company’s growth potential. Investors should consider these analyst ratings alongside key financial indicators to make informed decisions about investing in YMAB.
